A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
641
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
aliskiren
Sponsor
Novartis